Analogies between laryngeal and prostate cancers - frequent malignancies of the elderly

References

• Klotz L. Hormone therapy for patients with pros- tate carcinoma. Cancer 2000;88:3009–14
   PubMedGoogle Scholar
• Fujii T, Sato T, Yoshino K, et al. A clinical study of 1079 patients with laryngeal cancer. Nippon Jibiinkoka Gakkai Kaiho 1997;100:856–63
   PubMedGoogle Scholar
• Krecicki T, Zalesska-Krecicka M, Jagas M, et al. Laryngeal cancer in Lower Silesia: descriptive analysis of 501 cases. Oral Oncol 1998;34:377–80
   PubMedGoogle Scholar
• Raitiola HS, Pukander JS. Changing trends in the incidence of laryngeal cancer. Acta Oncol 1997; 36:33–6
   PubMed Web of Science ®Google Scholar
• Parkin DM, Whelan SL, Ferlay J, et al. Cancer Inci- dence in Five Continents. Volume VII. Publication No. 143. Lyon: IARC Scientific Publications, 1997
   Google Scholar
• Sandblom G, Dufmats M, Varenhorst E. Long- term survival rate in a Swedish population-based cohort of men with prostate cancer. Urology 2000; 56:442–7
   PubMed Web of Science ®Google Scholar
• Walsh PC, Retik AB, Stamey TA, et al. Campbell’s Urology. Philadelphia: WB Saunders, 1992: 1159–60
   Google Scholar
• Vermeulen A. Androgens in aging male. J Clin Endocrinol Metab 1991;73:221–4
   PubMed Web of Science ®Google Scholar
• Medras M, Rogucka E, Jankowska E. Bone mineral content and androgen–estrogen activity in a population of healthy male inhabitants of Wroclaw, Poland. Aging Male 1999;2:95–104
   Google Scholar
• Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metab- olites during aging. J Clin Endocrinol Metab 1997; 82:2396–402
   PubMed Web of Science ®Google Scholar
• Ferrini RL, Barrett Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147:750–4
   PubMed Web of Science ®Google Scholar
• Leifke E, Gorenoi V, Wichers C, et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf) 2000;53:689–95
   PubMedGoogle Scholar
• Sanchez Viscont G, Herrero L, et al. Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Mech Ageing Dev 1995; 82:19–29
   PubMedGoogle Scholar
• El Alfy M, Luu The V, Huang XF, et al. Localiza- tion of type 5 17beta-hydroxysteroid dehydro- genase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endo- crinology 1999;140:1481–91
   Google Scholar
• Labrie F, Belanger A, Luu-The V, et al. In Thijssen JHH, Niuewenhuyse H, eds. DHEA: A Compre- hensive Review. Carnforth, UK: Parthenon Publishing 1999:69–102
   Google Scholar
• Beckford NS, Rood SR, Schaid D, et al. Androgen stimulation and laryngeal development. Ann Otol Rhinol Laryngol 1985;94:634–40
   PubMed Web of Science ®Google Scholar
• Tuohimaa PT, Kallio S, Heinijoki J, et al. Andro- gen receptors in laryngeal carcinoma. Acta Otolaryngol (Stockh) 1981;91:149
   Google Scholar
• Toral I, Ciliv B, Gürsel B, et al. Androgen receptors in laryngeal carcinoma. Eur Arch Otorhinolaryngol 1990;247:244–6
   PubMedGoogle Scholar
• Marugo M, Cordone G, Fazzuoli L, et al. Cytosolic and nuclear androgen receptor activity in the cancer of the larynx. J Endocrinol Invest 1987;10:465–70
   PubMedGoogle Scholar
• Wang JQ, Dong Z, Zhu JG, et al. Androgen recep- tors in laryngeal carcinoma and their clinical signifi- cance. Chin Med J (Engl) 1991; 104:992–4
   PubMedGoogle Scholar
• Marsigliante S, Leo G, Resta L, et al. Steroid recep- tor status in malignant and non-malignant larynx. Ann Oncol 1992;3:387–92
   PubMed Web of Science ®Google Scholar
• Marsigliante S, Muscella A, Resta L, et al. Human larynx expresses isoforms of the oestrogen receptor. Cancer Lett 1996;99:191–6
   PubMed Web of Science ®Google Scholar
• Kleinsasser O. Tumors of the Larynx and Hypo- pharynx. Stuttgart, New York: Georg Thieme Verlag, Thieme Medical Publishers Inc., 1988:2–5
   Google Scholar
• Bassalyk LS, Iaglinski VA, Kuznetsova IM, et al. Sex steroid hormones, their receptors and local immu- nologic processes in experimental carcinogenesis of the larynx. Vopr Onkol 1985;31:71–7
   PubMedGoogle Scholar
• Sesti G, Marini MA, Briata P, et al. Androgens increase insulin receptor mRNA levels, insulin binding, and insulin responsiveness in HEp-2 larynx carcinoma cells. Mol Cell Endocrinol 1992;86:111–18
   PubMedGoogle Scholar
• Zhao X, Xiao X, Liu J. Effect of sexual hormones on proliferation of laryngeal carcinoma cell line HEp-2 in vitro. Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1994;29:149–51
   Google Scholar
• Bobin JY, Mayer M, Saez S. Role of androgens on larynx tumour growth. Cancer Treatm Rep 1979;63: 1195
   Google Scholar
• Kleemann D. Testosterone versus dihydro- testosterone effects on permanent squamous epithelial cancer cell lines of the larynx. Laryngorhinootologie 1993;72:402–5
   PubMedGoogle Scholar
• Medras M, Jozkow P, Krecicki T, et al. Androgeny a rak krtani. Otolaryngologia Polska 2000;5:523–9
   Google Scholar
• Filippov KG, Andreev VG, Sergeeva TN, et al. Tumor markers and hormonal homeostasis in laryngeal cancer. Med Radiol (Mosk) 1988;33:41–5
   PubMedGoogle Scholar
• Kushlinski NE, Bassalyk LS, Alferov VS, et al. Testosterone, albumin and sex steroid-binding globulin in the blood serum of patients with laryn- geal cancer. Vopr Onkol 1985;31:36–41
   Google Scholar
• Kambi V, Radel Z, Preelj J, et al. Testosterone – an etiological factor in the development of laryngeal carcinoma? HNO 1985;33:115–17
   PubMedGoogle Scholar
• Haidoutova R, Melamed M, Dimitrova S, et al. Investigations of serum testosterone levels in patients with laryngeal cancers. Arch Otorhino- laryngol 1985;241:213–17
   PubMedGoogle Scholar
• Szmeja Z, Kruk-Zagajewska A, Kozak W, et al. Correlation between the clinical stage of larynx cancer in male and female and levels of steroid hor- mones in serum. Otolaryngol Pol 1996;50:21–31
   PubMedGoogle Scholar
• Santner SJ, Albertson B, Zhang GY, et al. Compar- ative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 1998;83:2104–9
   PubMed Web of Science ®Google Scholar
• Makridakis N, Ross RK, Pike MC, et al. A preva- lent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997; 57:1020–2
   PubMed Web of Science ®Google Scholar
• Hayes RB, de Jong FH, Raatgever J, et al. Physical characteristics and factors related to sexual develop- ment and behaviour and the risk for prostatic cancer. Eur J Cancer Prev 1992;1:239–45
   PubMedGoogle Scholar
• Demark Wahnefried W, Lesko SM, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997;18:495–500
   PubMedGoogle Scholar
• Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118–26
   PubMed Web of Science ®Google Scholar
• Medras M, Basiewicz A, Polkowski P, et al. Evalua- tion of the antiandrogen activity in men presenting benign prostatic hyperplasia and prostatic carci- noma. Int J Androl 1997;(Suppl 1):81–3
   Google Scholar
• Mantzoros CS, Tzonou A, Signorello LB, et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–18
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Andro- gen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474–8
   PubMed Web of Science ®Google Scholar
• Vainas G, Pasaitou V, Galaktidou G, et al. The role of somatostatin analogues in complete anti- androgen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res 1997;16:119–26
   PubMed Web of Science ®Google Scholar
• Marelli MM, Limonta P, Maggi R, et al. Growth- inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000;45:238–44
   PubMed Web of Science ®Google Scholar
• Bartsch C, Bartsch H. Significance of melatonin in malignant diseases. Wien Klin Wochenschr 1997;109:722–9
   PubMedGoogle Scholar
• Carlström K, Stege R. Testicular and adreno- cortical function in men with prostatic cancer and in healthy age-matched controls. Br J Urol 1997;79:427–31
   PubMedGoogle Scholar
• Witjes JA, Debruyne FM. Drug treatment of pros- tatic carcinoma. Ned Tijdschr Geneeskd 1997;141:1855–8
   PubMedGoogle Scholar
• Kambic V, Radsel Z, Prezelj J, et al. Testosterone – an etiological factor in the development of laryn- geal carcinoma? HNO 1985;33:115–17
   PubMedGoogle Scholar